and Media

Investor Overview

Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

  • Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] was approved by the FDA on May 3, 2018. Learn more.
  • Bevyxxa® (betrixaban) was approved by the FDA on June 23, 2017. Learn more.
  • Cerdulatinib – Investigational, oral, dual-spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitior. Portola has worldwide rights to develop and commercialize cerdulatinib. Learn more.
Stock Info
Upcoming Events
Tuesday, January 14, 2020
7:00am PST

More ›

Corporate Presentation
Recent News
Jan 9, 2020

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced preliminary unaudited Andexxa global net revenues for the fourth quarter and full year 2019. For the fourth quarter, the Company...

Dec 23, 2019

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020. The event is scheduled to take place on

Dec 17, 2019

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its support of the American Heart Association®/American Stroke Association's® newest initiative for enhanced awareness and...

More ›

Annual Report